Vical Announces Results of Multiple NIH Phase II HIV Vaccine Trials

Results from a series of HIV vaccine Phase IIa clinical trials, using a plasmid DNA vaccine developed by the NIH Vaccine Research Center and manufactured by Vical, reinforced Phase I conclusions that a DNA prime-adenoviral vector boost vaccine regimen was safe and well-tolerated, and effective in inducing T-cell immune responses in up to 70 percent of the vaccine recipients, Vical reported.

According to Vical, the trials involved priming an immune response with three doses of a plasmid DNA vaccine over a two-month period and boosting the response with a single dose of adenoviral vector vaccine at six months.

The three trials, collectively known as TRIAD, were conducted by the National Institute of Allergy and Infectious Diseases HIV Trials Vaccine Network, the International AIDS Vaccine Initiative and the U.S. Military HIV Research Program.